OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings

All NewsJune 2, 2026

OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward FDA, EMA and TGA regulatory filings.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT